Comparative Pharmacology
Head-to-head clinical analysis: CEPHRADINE versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHRADINE versus SUPRAX.
CEPHRADINE vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephradine is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
250-500 mg orally every 6 hours; 500 mg to 1 g intramuscularly or intravenously every 6 hours. Maximum: 4 g/day.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life 0.5–1.5 hours (normal renal function); prolonged to 6–15 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Primarily renal (≥90% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<10%).
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic